Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib + Azacitidine in Untreated IDH1-Mutated AML
NCT03173248Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- Jun 2017
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of ivosidenib in acute myeloid leukemia (AML), sponsored by Servier. Started Jun 2017; status: active, not recruiting.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03173248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173248.